Novel Thienopyridines as RIPK2 Inhibitors for Treating Inflammatory Bowel Disease
Ram W. Sabnis
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTNovel Thienopyridines as RIPK2 Inhibitors for Treating Inflammatory Bowel DiseaseRam W. Sabnis*Ram W. SabnisSmith, Gambrell & Russell LLP, 1230 Peachtree Street NE, Suite 3100, Atlanta, Georgia 30309, United States*Email: [email protected]More by Ram W. Sabnishttp://orcid.org/0000-0001-7289-0581Cite this: ACS Med. Chem. Lett. 2020, 11, 12, 2366–2367Publication Date (Web):November 19, 2020Publication History Received9 November 2020Published online19 November 2020Published inissue 10 December 2020https://doi.org/10.1021/acsmedchemlett.0c00591Copyright © 2020 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views1457Altmetric-Citations4LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (768 KB) Get e-AlertsSUBJECTS:Diseases and disorders,Group 17 compounds,Inflammation,Inhibition,Inhibitors Get e-Alerts